Q3 2025 saw major clinical and strategic advances, including validation of Platin-DRP® for both cisplatin and carboplatin, new breast cancer data, and a win at a major entrepreneurship contest in China. Financials showed a net loss, strong equity ratio, and successful capital raises.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.